Pfizer Inc. (PFE)

39.38
NYSE
Prev Close 39.38
Day Low/High 0.00 / 0.00
52 Wk Low/High 34.37 / 46.47
Exchange NYSE
Shares Outstanding 5551.81B
Market Cap 218.63B
Div & Yield N.A. (N.A)
Pfizer Invites Public To View And Listen To Webcast Of January 29 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of January 29 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Seagate Technology, Macy's and a Dozen Other Dividend Stocks to Buy Here

Seagate Technology, Macy's and a Dozen Other Dividend Stocks to Buy Here

Focus on high-quality dividend payers as we move toward a possible yield-curve inversion and U.S. recession.

Kineta Enters Research Collaboration And License Agreement With Pfizer To Develop New Cancer Immunotherapies

Kineta Enters Research Collaboration And License Agreement With Pfizer To Develop New Cancer Immunotherapies

Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments

Johnson & Johnson Shares Plunge After Report It Knew of Asbestos in Baby Powder

Johnson & Johnson Shares Plunge After Report It Knew of Asbestos in Baby Powder

Johnson & Johnson shares plunged the most in more than 15 years Friday following a report that said the company knew for decades that its iconic baby powder sometimes contained asbestos and failed to alert authorities.

Pfizer Boosts Q1 Dividend, Launches $10 Billion Buyback as Read Says Farewell

Pfizer Boosts Q1 Dividend, Launches $10 Billion Buyback as Read Says Farewell

Pfizer shares traded lower Friday even as the pharmaceutical group boosted it latest quarterly dividend and said it would buyback another $10 million in company stock in what may be the last corporate act of outgoing CEO Ian Read.

Pfizer Declares First-Quarter 2019 Dividend

Pfizer Declares First-Quarter 2019 Dividend

The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company's common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019.

Pfizer Receives Positive CHMP Opinion For Oncology Biosimilar, ZIRABEV™ (bevacizumab)

Pfizer Receives Positive CHMP Opinion For Oncology Biosimilar, ZIRABEV™ (bevacizumab)

Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for ZIRABEV ™ (bevacizumab), a potential...

Pfizer Initiates Phase 3 Program For 20-Valent Pneumococcal Conjugate Vaccine For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Initiates Phase 3 Program For 20-Valent Pneumococcal Conjugate Vaccine For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Inc. (NYSE:PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes...

Pfizer Becomes #12 Most Shorted Dow Stock, Replacing Intel

Pfizer Becomes #12 Most Shorted Dow Stock, Replacing Intel

The most recent short interest data has been released for the 11/30/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Stocks End Mixed as China Trade Progress Offsets D.C. Dysfunction

Stocks are mixed Tuesday as Donald Trump and top Democratic leaders clash over border security.

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

The CEOs who bring in the most money every year may not be who you expect. Who are the highest-paid CEOs?

Pfizer Slips After JPMorgan Downgrade on Patent Cycle Concerns

Pfizer Slips After JPMorgan Downgrade on Patent Cycle Concerns

Pfizer shares slipped Tuesday after analysts at JPMorgan lowered their rating for the drugmaker amid concerns of the loss of exclusivity on one of its key pain treatments.

Wall Street Futures Jump Higher, Global Markets Rally on US-China Trade Progress

Wall Street Futures Jump Higher, Global Markets Rally on US-China Trade Progress

Global stocks edged higher Tuesday, with investors reacting cautiously to progress in U.S.-China trade talks but still unnerved by the ongoing political chaos surrounding Britain's Brexit vote, as bond investor prep for a series of Treasury auctions in the United States.

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting

Pfizer Inc. (NYSE:PFE) announced today at the American Society of Hematology Annual Meeting that the REFLECTIONS B328-06 study, a comparative safety and efficacy study of PF-05280586 versus Rituxan ®/MabThera ® (rituximab-EU) i, met its primary endpoint...

Pfizer Is in Breakout-Mode This Fall: Chart

Pfizer Is in Breakout-Mode This Fall: Chart

This healthcare stock looks healthy for your portfolio amid the volatility.

Pfizer Reaches A Global Agreement With AbbVie

Pfizer Reaches A Global Agreement With AbbVie

Pfizer Inc. (NYSE:PFE) today announced that it has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar.

Pfizer Receives Six Months Pediatric Exclusivity For LYRICA® (pregabalin)

Pfizer Receives Six Months Pediatric Exclusivity For LYRICA® (pregabalin)

Pfizer Inc. (NYSE: PFE) today announced that the U.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Chris Boshoff, senior vice president and head, Immuno-Oncology, Early Development and Translational Oncology, at the Evercore ISI HealthConX Conference on...

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer pushes higher on price increases.

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Pharma could be the best parking spot for your money if the market keeps trending downward.

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Monday Madness: Don't Be Afraid of the Big, Bad Bear

Here's what you're missing on TheStreet.

The Market Is 'Full Blown Bear,' Says Jim Cramer

The Market Is 'Full Blown Bear,' Says Jim Cramer

Worried about the market? Jim Cramer has some advice for investors.

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing

Shares of the New York City-based pharmaceutical giant are rising on Monday.

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer, Other Pharma Stocks Should Continue to Do Well Amid Market Volatility

Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer Reacts to Pfizer's Drug Hikes

Jim Cramer responds to the news that the drug company, Pfizer, has hiked rates.

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Pfizer Could Rally in the Weeks Ahead as Investors Look Beyond Today's Headline

Let's check our indicators.

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.

TheStreet Quant Rating: B (Buy)